Does High Myopia have a cure?

Currently, there is no definitive cure for High Myopia that can reverse the underlying elongation of the eyeball or restore structural integrity to the retina. However, significant advancements in clinical research are shifting the focus from simple vision correction to disease modification, aiming to slow or halt the progression of High Myopia and prevent vision-threatening complications.

Is there a cure for High Myopia?

At this time, medicine does not offer a cure that can "shrink" the eye or eliminate the genetic and environmental factors driving High Myopia. Because High Myopia (typically defined as a spherical equivalent of -6.00 diopters or worse, or an axial length greater than 26.5 mm) involves structural changes to the globe, current clinical interventions are focused on myopia control. These treatments aim to slow the axial elongation of the eye during childhood and adolescence, thereby reducing the risk of later-life pathologies like myopic maculopathy, retinal detachment, and glaucoma.

What treatments are available for symptom management?

While we wait for breakthroughs in regenerative medicine, clinicians use a multi-faceted approach to manage High Myopia and mitigate its impact on long-term ocular health. Current strategies include:

• Low-dose Atropine drops: Daily use of low-concentration atropine eye drops has been clinically proven in studies like the ATOM trials to slow the progression of myopia in children.


• Orthokeratology (Ortho-K): Specially designed rigid gas-permeable contact lenses worn overnight to temporarily reshape the cornea, which may also slow axial growth.


• Peripheral Defocus Spectacle Lenses: Newer lens technologies designed to reduce peripheral hyperopic defocus, a known stimulus for eye growth.


• Standard Vision Correction: High-index lenses or contact lenses to manage refractive error, though these do not treat the underlying structural elongation of High Myopia.

What are the most promising research directions for a cure?

The medical research community is currently investigating therapies that target the molecular pathways of scleral remodeling. The sclera is the "white" of the eye, and in patients with High Myopia, this tissue becomes thin and unstable. Researchers are exploring:

1. Scleral Cross-linking: Using UV light or chemical agents to increase the stiffness of the scleral collagen, physically preventing the eye from stretching further.


2. Gene Therapy: Identifying genetic markers (such as those found in OMIM entries for high myopia) to develop targeted therapies that regulate the growth factors responsible for eye elongation.


3. Precision Medicine: Utilizing AI-driven imaging to predict which pediatric patients are at the highest risk for developing pathological High Myopia, allowing for early, aggressive intervention.

When can patients expect a breakthrough?

While gene-based cures are still in the experimental stages, the timeline for "disease-modifying" treatments is accelerating. Clinical trials for pharmacological agents that stabilize the sclera are currently active. While a total cure remains a long-term goal, the next 5 to 10 years are expected to yield significantly more effective tools to prevent the progression of High Myopia into vision-threatening stages.

Next steps

• Consult a specialist: Work with an ophthalmologist or optometrist who specializes in myopia management rather than just standard refractive correction.


• Stay informed: Follow updates from the International Myopia Institute (IMI) for the latest consensus reports.


• Connect with others: Join the 78 members of the DiseaseMaps.org community to share experiences and learn about regional clinical trial opportunities.


• Participate in research: Search ClinicalTrials.gov for "High Myopia" to see if you or your family members qualify for ongoing studies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; always consult with your ophthalmologist regarding your specific vision health.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Myopia resources.


• International Myopia Institute (IMI) - Clinical management guidelines.


• OMIM (Online Mendelian Inheritance in Man) - Genetic database for hereditary high myopia.


• PubMed - Recent systematic reviews on atropine and scleral cross-linking in high myopia.